MMI-0100|cas:1039342-24-9|西域试剂

MMI-0100,99.55%

产品编号：Bellancom-P3412| CAS NO：1039342-24-9| 分子式：C₉₈H₁₇₁N₃₇O₂₆| 分子量：2283.64

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P3412	￥3000.00	杭州北京（现货）
Bellancom-P3412	￥4800.00	杭州北京（现货）
Bellancom-P3412	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MMI-0100

产品介绍

MMI-0100 是一种细胞渗透性肽抑制剂，抑制丝裂原活化蛋白激酶活化蛋白激酶 II (MK2)。MMI-0100 在体内外减少内膜增生。MMI-0100 抑制 IL-6 表达而不影响 IL-8 表达。MMI-0100 抑制纤维化过程，例如静脉移植疾病。

生物活性

MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease.

体外研究

Naphthofluorescein (compound 19) (0-10 μM; 24 hours) suppresses the HIF-1 reporter activity in a concentration-dependent manner. .
MMI-0100 (0.25 and 0.5 mM; 24 hours) slightly increases cell proliferation in both cell types compared to control cells treated with 20 ng/ml TNF-α alone.
MMI-0100 (1 mM) treatment also increases both EC (11%) and SMC (7%) proliferation as compared to control, this response is not as robust as that induced by treatment with 0.5 mM MMI-0100.
MMI-0100 does not induce EC apoptosis at any dose.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	human endothelial cell (EC) and smooth muscle cell (SMC)
Concentration:	0.25, 0.5, and 1 mM
Incubation Time:	24 hours
Result:	Slightly increased cell proliferation in both cell types compared to control cells.

体内研究
(In Vivo)

MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12-week-old C57Bl/6 wild type mice (intimal hyperplasia)
Dosage:	100 μM
Administration:	vein graft, 28 days
Result:	Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts.

体内研究

MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12-week-old C57Bl/6 wild type mice (intimal hyperplasia)
Dosage:	100 μM
Administration:	vein graft, 28 days
Result:	Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts.

体内研究

MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12-week-old C57Bl/6 wild type mice (intimal hyperplasia)
Dosage:	100 μM
Administration:	vein graft, 28 days
Result:	Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (43.79 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.4379 mL	2.1895 mL	4.3790 mL
5 mM	0.0876 mL	0.4379 mL	0.8758 mL
10 mM	0.0438 mL	0.2189 mL	0.4379 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶